Evaluation of the contemporary occurrence rates of metallo-β-lactamases in multidrug-resistant Gram-negative bacilli in Japan:: report from the SENTRY Antimicrobial Surveillance Program (1998-2002)

被引:25
作者
Jones, RN [1 ]
Deshpande, LM
Bell, JM
Turnidge, JD
Kohno, S
Hirakata, Y
Ono, Y
Miyazawa, Y
Kawakama, S
Inoue, M
Hirata, Y
Toleman, MA
机构
[1] Jones Grp, JMI Lab, N Liberty, IA USA
[2] Womens & Childrens Hosp, Adelaide, SA, Australia
[3] Nagasaki Univ, Sch Med, Nagasaki 852, Japan
[4] Teikyo Univ, Sch Med, Tokyo 173, Japan
[5] Kitasato Univ, Sch Med, Kanagawa, Japan
[6] Univ Bristol, BCARE, Bristol, Avon, England
关键词
metallo-beta-lactamases; Japan; SENTRY program; resistance; integrons; carbapenems;
D O I
10.1016/j.diagmicrobio.2004.04.007
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Metallo-beta-lactamases (MbetaL) were initially characterized in Japan, usually of the IMP-type, and found in Pseudomonas aeruginosa (PSA), Acinetobacter spp. (ACB), or Serratia marcescens (SM). The number of MbetaL types has increased worldwide, but geographic dissemination within Japan has appeared limited. This study compares baseline levels of MbetaL resistance from two 22-center studies (1996-1997) to the longitudinal sample (3 sites) of Japanese isolates from the SENTRY Antimicrobial Surveillance Program (1998-2002). All minimal inhibitory concentration results were determined by reference methods. A total of 26.8% PSA, 3.4% ACB, and 3.1% Enterobacteriaceae (enterobacters and SM) with resistance to monitored carbapenems (CARB) (minimal inhibitory concentration, greater than or equal to8 mug/mL) were screened for MbetaL production by disk approximation tests (EDTA and 2-MPA inhibitors), CARB hydrolysis by enzyme extracts. and selected PCR primers for known MbetaL types. All MbetaL-positive strains (10) were sequenced to determine enzyme identification. Clonality in each center was determined by automated ribotyping and PFGE. The CARB susceptibility rates in PSA decreased (80.7% to 62.0%) over the monitored interval (1998-2002), but varied by medical center location. Among CARB-resistant isolates, 10.8% were attributed to MOL strains (1.1% of all PSA tested). MOL identification showed the following: five PSA (three IMP-1, two IMP-2), four SM (one IMP-1, two IMP-1 + OXA-1, and one IMP-11). Also a single ACB had an IMP-1. Eight of 10 MbetaL isolations occurred between 2000 and 2002: four occurred in 2002. BRL42715, an AMP-C inhibitor, confirmed AMP-C-mediated resistance in 87.3% of PSA, and outer membrane protein changes were also discovered by membrane studies. Prior results (22 sites, 1997-1998) showed CARB resistance at 22.4-25.6% and 0.5-0.9% MbetaLs (IMP-1) overall; it was slightly elevated in this SENTRY Program sample. In conclusion, MbetaL-producing strains from several species persist in Japan, but represent a distinct minority of all CARB-resistant strains (1998-2002). Although MbetaL rates appear generally stable in Japan, continued surveillance for these mechanisms seems to be a prudent practice, because of the mobility of the genetic determinants and the emergence of novel enzyme types, especially among the Enterobacteriaceae. (C) 2004 Elsevier Inc. All rights reserved.
引用
收藏
页码:289 / 294
页数:6
相关论文
共 31 条
[1]   Trends in antimicrobial-drug resistance in Japan [J].
Arakawa, Y ;
Ike, Y ;
Nagasawa, M ;
Shibata, N ;
Doi, Y ;
Shibayama, K ;
Yagi, T ;
Kurata, T .
EMERGING INFECTIOUS DISEASES, 2000, 6 (06) :572-575
[2]  
Arakawa Y, 2000, J CLIN MICROBIOL, V38, P40
[3]  
CASTANHEIRA M, 2003, 43 INT C ANT AG CHEM, P76
[4]   INVITRO EVALUATION OF BRL 42715, A NOVEL BETA-LACTAMASE INHIBITOR [J].
COLEMAN, K ;
GRIFFIN, DRJ ;
PAGE, JWJ ;
UPSHON, PA .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1989, 33 (09) :1580-1587
[5]   IMP-12, a new plasmid-encoded metallo-β-lactamase from a Pseudomonas putida clinical isolate [J].
Docquier, JD ;
Riccio, ML ;
Mugnaioli, C ;
Luzzaro, F ;
Endimiani, A ;
Toniolo, A ;
Amicosante, G ;
Rossolini, GM .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2003, 47 (05) :1522-1528
[6]   Clinical and bacteriological characteristics of IMP-type metallo-β-lactamase-producing Pseudomonas aeruginosa [J].
Hirakata, Y ;
Yamaguchi, T ;
Nakano, M ;
Izumikawa, K ;
Mine, M ;
Aoki, S ;
Kondoh, A ;
Matsuda, J ;
Hirayama, M ;
Yanagihara, K ;
Miyazaki, Y ;
Tomono, K ;
Yamada, Y ;
Kamihira, S ;
Kohno, S .
CLINICAL INFECTIOUS DISEASES, 2003, 37 (01) :26-32
[7]   PLASMID-MEDIATED DISSEMINATION OF THE METALLO-BETA-LACTAMASE GENE BLA(IMP) AMONG CLINICALLY ISOLATED STRAINS OF SERRATIA-MARCESCENS [J].
ITO, H ;
ARAKAWA, Y ;
OHSUKA, S ;
WACHAROTAYANKUN, R ;
KATO, N ;
OHTA, M .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1995, 39 (04) :824-829
[8]   Endemic carbapenem-resistant Pseudomonas aeruginosa with acquired metallo-β-lactamase determinants in European hospital [J].
Lagatolla, C ;
Tonin, EA ;
Monti-Bragadin, C ;
Dolzani, L ;
Gombac, F ;
Bearzi, C ;
Edalucci, E ;
Gionechetti, F ;
Rossolini, GM .
EMERGING INFECTIOUS DISEASES, 2004, 10 (03) :535-538
[9]   Cloning and characterization of blaVIM, a new integron-borne metallo-β-lactamase gene from a Pseudomonas aeruginosa clinical isolate [J].
Lauretti, L ;
Riccio, ML ;
Mazzariol, A ;
Cornaglia, G ;
Amicosante, G ;
Fontana, R ;
Rossolini, GM .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1999, 43 (07) :1584-1590
[10]   Evaluation of the Hodge test and the imipenem-EDTA double-disk synergy test for differentiating metallo-β-lactamase-producing isolates of Pseudomonas spp. and Acinetobacter spp. [J].
Lee, K ;
Lim, YS ;
Yong, D ;
Yum, JH ;
Chong, Y .
JOURNAL OF CLINICAL MICROBIOLOGY, 2003, 41 (10) :4623-4629